Cognitive & Neuropeptides
Nootropic and neuroprotective research peptides from the Russian academic tradition. Selank (TP-7) as a Tuftsin analogue for studies on anxiolysis and immune modulation, Semax as an ACTH fragment 4-10 for research on BDNF/NGF expression and cognitive resilience, plus the popular Semax-Selank combination. All three have been studied since the 1990s at the Institute of Molecular Genetics (RAS) in Moscow and are clinically approved in Russia, while remaining research compounds in the West. Every batch ships with a batch-specific HPLC CoA from Janoshik Analytical.
All products
Related research
June 16, 2026
DSIP (Delta-Sleep-Inducing-Peptide): The Unsolved Riddle of Sleep Research
DSIP: a research nonapeptide with no confirmed receptor, three research strands, a very short half-life, and the 2026 FDA story. Research use only.
Read more →
June 14, 2026
Semax and Alzheimer's: What the 2025 Amyloid Plaque Study Means
Acta Naturae 2025 (Radchenko et al.): Intranasal Semax cuts amyloid plaques 2.8-fold cortical and 2.6-fold hippocampal in an Alzheimer mouse model.
Read more →
June 4, 2026
Semax vs Selank vs the Stack: Which Nootropic Peptide for Your Research Goal?
Semax, Selank and the combined stack compared: mechanism, evidence base and an honest assessment. The decision guide for nootropic research.
Read more →




